Commentary|Videos|April 3, 2025
PRO Data for Mirvetuximab Soravtansine From MIRASOL in FRa+ Platinum-Resistant Ovarian Cancer
Fact checked by: Chris Ryan
Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, on patient-reported outcome data for mirvetuximab soravtansine in platinum-resistant ovarian cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
Experts convened to discuss ADC sequencing strategies, biomarker testing infrastructure, and emerging data across cervical, ovarian, and endometrial cancers.
The top 5 OncLive TV videos of the week cover insights in breast cancer, lymphoma, melanoma, prostate cancer, and ovarian cancer.
The FDA accepted for review a sBLA for subcutaneous mosunetuzumab plus polatuzumab vedotin in LBCL, a BLA for ozekibart in chondrosarcoma, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
June’s GI Rewind: CRC, Gastric Cancer See Several “Firsts” With FDA Review of Adjuvant IO, Global Approval of BRAF-Targeted and CAR T-Cell Therapies
2
Namodenoson Meets Safety End Point in PDAC, Shows Durable Survival Outcomes Pretreated Subgroup
3
Belantamab Mafodotin Yields Sustained MRD Negativity in R/R Myeloma
4
FDA Approval Positions Belzutifan Plus Pembrolizumab as a New Adjuvant Standard in ccRCC
5